DATE: March 9, 2021

ALL PLAN LETTER 20-004 (REVISED)

TO: ALL MEDI-CAL MANAGED CARE HEALTH PLANS

SUBJECT: EMERGENCY GUIDANCE FOR MEDI-CAL MANAGED CARE HEALTH PLANS IN RESPONSE TO COVID-19

PURPOSE:
The purpose of this All Plan Letter (APL) is to provide information to Medi-Cal managed care health plans (MCPs) on temporary changes to federal requirements as a result of the ongoing global COVID-19 pandemic. As the Department of Health Care Services (DHCS) continues to respond to concerns and changing circumstances resulting from the pandemic, DHCS will provide updated guidance to MCPs. Revised text is found in *italics*.

BACKGROUND:
In light of both the federal Health and Human Services Secretary’s January 31, 2020, public health emergency (PHE) declaration, which was renewed on January 7, 2021, as well as the President’s March 13, 2020, national emergency declaration, DHCS began exploring options to temporarily waive and/or modify certain Medicaid and Children’s Health Insurance Program requirements. On March 16, 2020, March 19, 2020, April 10, 2020, and December 24, 2020, DHCS submitted requests to waive or modify a number of federal requirements under Section 1135 of the Social Security Act (Title 42 United States Code section 1320b-5) to the Centers for Medicare and Medicaid Services (CMS). DHCS’ Section 1135 Waiver submissions requested various flexibilities related to COVID-19. On March 23, 2020, May 8, 2020, August 19, 2020 and December 31, 2020, CMS issued approval letters to DHCS authorizing specific Section 1135 flexibilities.¹

To streamline the Section 1135 Waiver request and approval process, CMS issued a number of blanket waivers for many Medicare provisions that do not require individualized approval. While not all of these waivers apply to Medicaid, CMS has provided guidance for specified health care providers regarding blanket waivers on a variety of topics, including, but not limited to, Rural Health Clinics (RHCs) and Federally Qualified Health Centers (FQHCs); Long Term Care (LTC) Facilities and Skilled Nursing Facilities and/or

---

¹ The Section 1135 Waiver requests and CMS approval letters can be found on the DHCS COVID-19 Response webpage under Waiver Requests & Approvals – 1135 Waiver Requests & Approvals at the following link: [https://www.dhcs.ca.gov/Pages/DHCS-COVID%2E2%80%919-Response.aspx](https://www.dhcs.ca.gov/Pages/DHCS-COVID%2E2%80%919-Response.aspx)
Nursing Facilities; Durable Medical Equipment, Prosthetics, Orthotics and Supplies; and Provider Enrollment.²

DHCS will provide updates to this guidance to reflect any additional Section 1135 Waiver approvals not reflected in the above mentioned approval letters, as appropriate.

On March 6, 2020, DHCS issued a Memorandum (Memo) to MCPs to remind them of existing contractual and legal requirements to ensure access to medically necessary services in a timely manner, in particular as related to COVID-19. DHCS subsequently updated the Memo on March 16, 2020 to include additional guidance. This APL incorporates the guidance provided in that Memo.

On May 13, 2020, and August 20, 2020, CMS issued letters approving DHCS’ proposed amendments to add section 7.4 Medicaid Disaster Relief for the COVID-19 National Emergency to California’s Medicaid State Plan.³ State Plan Amendments (SPA) 20-0024 and 20-0025 implement temporary policies, different from those otherwise applied under California’s Medicaid state plan, during the period of the Presidential and Secretarial emergency declarations related to the COVID-19 outbreak. DHCS guidance on various temporary policies included in SPA 20-0024 and 20-0025 are posted on the DHCS COVID-19 Response webpage under Waiver Requests & Approvals - State Plan Requests & Approvals; relevant changes affecting the Medi-Cal managed care delivery system are also addressed in this APL.

POLICY:

Part 1 – Section 1135 Waiver Approvals

CMS’ responses to DHCS’ flexibility requests are applicable, in part, to the Medi-Cal managed care delivery system, including the following:

State Fair Hearings

DHCS has received CMS approval to extend the timeframe for MCP members to request a state fair hearing (SFH). For details, refer to the March 23rd CMS approval letter and the Supplement to APL 17-006, titled “Emergency State Fair Hearing Timeframe Change – Managed Care.”⁴

---


³ SPA requests and approvals can be found on the DHCS COVID-19 Response webpage under Waiver Requests & Approvals – State Plan Amendments Requests & Approvals.

⁴ APLs, along with any Supplements, can be found at: https://www.dhcs.ca.gov/formsandpubs/Pages/AllPlanLetters.aspx
In addition, on December 31, 2020, DHCS received approval from CMS to modify the timeframe under 42 Code of Federal Regulations (CFR) section 438.420(a)(i) related to the continuation of benefits (i.e.; Aid Paid Pending (APP)). This APL modifies the guidance in APL 17-006 for the duration of the PHE.

Through the duration of the PHE, when a member’s appeal involves the termination, suspension, or reduction of previously authorized services, MCPs must provide APP when the member timely files an appeal within the current timeframes (i.e.; on or before the later of the following: within 10 calendar days of the Notice of Action (NOA), or prior to the MCP’s intended date of the proposed action), or reinstate APP when the member files an appeal between 11 and 30 days of the NOA, if the MCP has not made a final decision on the appeal. In addition, if the MCP provided APP for the member pending the outcome of an appeal, the MCP must provide APP pending the outcome of a SFH, if the member requests a SFH within the current 10 calendar timeframe, or reinstate APP when the member requests a SFH between 11 and 30 days of the Notice of Appeal Resolution, if there is not a final decision on the SFH.

MCPs must provide APP regardless of whether the member makes a separate request for APP, when the member timely files an appeal and SFH regarding an MCP’s decision to terminate, suspend or reduce services. The MCP is prohibited from seeking reimbursement or payment for the additional days of services furnished during this period.

Provider Enrollment/Screening

In the March 23, 2020 response, CMS approved certain temporary flexibilities for provider screening and enrollment. DHCS has issued guidance regarding these flexibilities for provider enrollment that applies to both Medi-Cal Fee-For-Service (FFS) and managed care provider screening and enrollment. This guidance is listed as "Guidance for Emergency Medi-Cal Provider Enrollment" on the DHCS COVID-19 Response webpage under Providers & Partners – Guidance for Multiple Provider Types, and allows for an emergency provider enrollment process. MCPs that conduct provider enrollment through their own process must implement a similar process to that contained in this guidance.

MCPs that rely on DHCS’ Provider Enrollment Division (PED) must direct potential new providers to the process outlined in the DHCS guidance referenced above. Immediately upon successful completion of the emergency enrollment application process through PED, providers will receive an approval email message, and an approval letter in DHCS’ Provider Application and Validation for Enrollment portal, stating that they have been granted enrollment for 60 days, with the possibility of extension in 60-day increments. MCPs must require these providers to submit a copy of their approval letter as proof of the approved temporary enrollment prior to providing services to MCP members.
Prior Authorization
While the Section 1135 Waiver approvals relating to prior authorization focus on Medi-Cal FFS, CMS, in its COVID-19 Frequently Asked Questions for State Medicaid and Children’s Health Insurance Program (CHIP) Agencies, indicated that states may modify prior authorization requirements for Medicaid managed care. For Medi-Cal managed care, DHCS is exercising this authority to require MCPs to waive prior authorization requirements for COVID-19 related testing and treatment services. In addition, MCPs are strongly encouraged to implement expedited authorization procedures for other services during the COVID-19 PHE. For details, refer to the “FFS Prior Authorization – Section 1135 Waiver Flexibilities” guidance, including any subsequently released updates to this guidance, which is available on the DHCS COVID-19 Response webpage under Providers & Partners – Guidance for Multiple Provider Types.

COVID-19 Testing
MCPs must adhere to the COVID-19 testing requirements outlined in the COVID-19 Virus and Antibody Testing guidance document, which can be found on the DHCS COVID-19 Response webpage under Providers & Partners – Guidance for Multiple Provider Types.

DHCS will reimburse Medi-Cal FFS providers for COVID-19 testing based on the Medicare fee schedule. Unless otherwise agreed to between the MCP and the provider, DHCS encourages MCPs to reimburse providers for COVID-19 testing at the Medicare fee schedule rates. MCPs should refer to the Medi-Cal provider manual for additional information about COVID-19 billing codes.5

Provision of Care in Alternative Settings, Hospital Capacity, and Blanket Section 1135 Waiver Flexibilities for Medicare and Medicaid Enrolled Providers Relative to COVID-19
Based on the guidance issued by CMS, DHCS issued the “Provision of Care in Alternative Setting, Hospital Capacity, and Blanket Section 1135 Waiver Flexibilities for Medicare and Medicaid Enrolled Providers Relative to COVID-19” guidance document, which will remain in effect through the end of the COVID-19 PHE. This guidance is applicable to MCPs, including any subsequently released updates to this guidance. The link to Providing Care in Alternate Settings, Hospital Capacity, Transportation, Blanket 1135 Flexibilities can be found on the DHCS COVID-19 Response webpage under Providers & Partners – Guidance for Multiple Provider Types.

Pharmacy
On April 3, 2020, DHCS issued the “Off-label and/or Investigational Drugs Used to Treat COVID-19 and/or Related Conditions” guidance document. This guidance provides

5The Pathology: Microbiology Provider Manual can be found at the following link: https://files.medi-cal.ca.gov/pubsdoco/publications/masters-mtp/Part2/pathmicro.pdf
information regarding temporary flexibilities in dispensing/administration policies governing off-label and investigational use of medications used to treat COVID-19 under the Medi-Cal FFS pharmacy benefit. In addition, DHCS issued the “Information Regarding the Use of Subcutaneous Depot Medroxyprogesterone Acetate During the 2019 Novel Coronavirus Public Health Emergency” guidance document. This guidance temporarily allows for pharmacy dispensing of Subcutaneous Depot Medroxyprogesterone Acetate directly to beneficiaries for self-administration at home. MCPs must follow the requirements contained in these pharmacy guidance documents, including any subsequently released updates to this guidance. The link to the Fee-For-Service Pharmacy: Flexibilities for Off-Label/Investigational Drugs in COVID-19 Related Treatment and the Direct-to-Patient Dispensing of Subcutaneous Depot Medroxyprogesterone Acetate – COVID-19 Emergency guidance can be found on the DHCS COVID-19 Response webpage under Providers & Partners – Hospitals, Clinics, Pharmacies, and Other Facilities.

Part 2 – Additional Guidance to MCPs

As the State of California responds to the COVID-19 situation, DHCS is regularly updating and distributing guidance to MCPs, counties and providers. Please refer to the DHCS COVID-19 Response webpage for the most up-to-date information available. MCPs should send questions, concerns and reports of member access issues to their DHCS Managed Care Operations Division (MCOD) Contract Manager.

DHCS reminds MCPs that they must adhere to existing contractual requirements and state and federal laws requiring MCPs to ensure their members are able to access medically necessary services in a timely manner. MCPs must:

- Cover all medically necessary emergency care without prior authorization, whether that care is provided by an in-network or out-of-network provider.
- Comply with utilization review timeframes for approving requests for urgent and non-urgent covered services. MCPs are required to waive prior authorization requests for services, including screening and testing, related to COVID-19.
- Ensure their provider networks are adequate to handle an increase in the need for services, including offering access to out-of-network services where appropriate and required, as more COVID-19 cases emerge in California.
- Ensure members are not liable for balance bills from providers, including balance billing related to COVID-19 testing.
- Provide members with 24-hour access to an MCP representative with the authority to authorize services, and ensure that DHCS has contact information for that

---

6 Similar provisions are outlined in the Department of Managed Health Care (DMHC) APL 20-006, which applies to MCPs licensed by DMHC.
person. This contact information must be provided to the MCP’s MCOD Contract Manager upon request by DHCS.

MCPs must proactively ensure members can access all medically necessary screening and testing of COVID-19. To this end, the sections below provide further guidance on specific topics.

**Suicide Prevention Practices for Providers**
As the COVID-19 *PHE* continues, many Californians are experiencing secondary impacts on their mental health. The directors of DHCS and the California Department of Public Health collaborated with the California Surgeon General to write a letter to all California medical and behavioral health providers encouraging them to ask their patients the four “Ask Suicide-Screening Questions” developed by the National Institute of Mental Health. DHCS encourages MCPs to share this information with their network providers and subcontractors, as appropriate.

**Telehealth**
MCPs must work with their contracted providers to use telehealth services to deliver care when medically appropriate, as a means to limit members’ exposure to others who may be infected with COVID-19 and to increase provider capacity. Please refer to DHCS All Plan Letter 19-009 (REVISED), and the Supplement to APL 19-009 (REVISED) that was issued on March 18, 2020, for clarification on the Medi-Cal telehealth policy for the duration of the *PHE*.

In addition to existing Medi-Cal telehealth policies, DHCS also allows reimbursement for virtual communication, which includes a brief communication with another practitioner or with a patient for COVID-19 related services, who cannot or should not be physically present (face-to-face). For encounter reporting purposes, providers must use HCPCS codes G2010 and G2012 for brief virtual communications.

DHCS notes that the United States Department of Health and Human Services Office of Civil Rights (HHS-OCR) has clarified that it will exercise its enforcement discretion for noncompliance with the regulatory requirements under the Health Insurance Portability and Accountability Act (HIPAA). The HHS-OCR will not impose penalties against providers who use telehealth in good faith. Providers can use any non-public-facing remote communication (audio or video) product that is available to communicate with patients. Providers may use popular applications that allow for video chats, such as Apple FaceTime or Skype, to provide telehealth. Additional guidance regarding HHS-OCR’s

---


HIPAA enforcement can be found on HHS-OCR’s webpage. CMS has also issued guidance on the use of telehealth for providers dually certified in Medicare/Medicaid.

DHCS issued telehealth guidance related to DHCS’ Section 1135 Waiver and SPA 20-0024 approvals. DHCS has instructed all Medi-Cal providers, including Federally Qualified Health Centers (FQHC), Rural Health Clinics (RHC), and Indian Health Services (IHS) clinics to implement the guidance related to telehealth and virtual/telephonic communication modalities immediately in light of COVID-19. Accordingly, DHCS instructs MCPs to implement this guidance, including any subsequently released updates to this guidance, with their providers, and allow FQHCs, RHCs and IHS clinics to provide and bill for virtual/telephonic visits consistent with in person visits. Additionally, virtual/telephonic visits provided pursuant to this guidance are eligible for prospective payment system (PPS) rates, or all-inclusive rates, as applicable.

Well-Child Visits
Well-child visits or regular checkups are an important way to monitor children’s growth and development and ensure that children are up-to-date with their vaccinations. With California’s stay at home guidance, and federal guidance on non-essential medical procedures, DHCS recognizes that members/parent caregivers may be cautious about making medical appointments for well-child visits. Under the Early and Periodic Screening, Diagnostic, and Treatment benefit, Medi-Cal covers recommended vaccines, preventive care, and screening for infants and children as recommended by the American Academy of Pediatrics (AAP)/Bright Futures, and in accordance with the AAP Periodicity Schedule.

In light of COVID-19, the AAP has developed guidance on providing pediatric well-care during COVID-19, including guidance on the necessary use of telehealth during the COVID-19 pandemic.

---

8 The Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency on the HHS-OCR website is available at: https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/index.html
10 The Telehealth and Virtual Communications: Payment in FFS and Medi-Cal Managed Care guidance is available on the DHCS COVID-19 Response webpage under Providers & Partners – Guidance for Multiple Provider Types.
In accordance with the AAP guidance, and to ensure continued adherence to the Bright Futures guidelines, DHCS encourages MCPs to follow the AAP guidance mentioned above and to encourage their pediatric providers to discuss with members/parent caregivers the benefit of attending a well-child visit in person to receive necessary immunizations and screenings, in addition to the provision of services via telehealth.

To the extent there are components of the comprehensive well-child visit provided in-person (due to those components not being appropriately provided via telehealth) that are a continuation of companion services provided via virtual/telephonic communication, the provider should only bill for one encounter/visit.⁸

**Transportation**
MCPs must approve transportation requests in a timely manner if a member, who may be infected with COVID-19, needs to see a provider in person and requests transportation. MCPs are responsible for determining the appropriate mode of transportation required to meet the members’ medical needs, paying special attention to those with urgent needs such as dialysis or chemotherapy treatments. Please refer to DHCS’ “COVID-19 Guidance for Non-Emergency Medical Transportation (NEMT) and Non-Medical Transportation (NMT) Providers” for recommendations on safety procedures and protocols to help prevent the spread of COVID-19.¹³

**Pharmacy Services**
MCPs must act proactively to ensure member access to needed prescription medications.

Proactive steps MCPs should take include:

- Covering maintenance medications (both generic and brands) at a minimum 90 day supply. Medi-Cal allows up to a 100-day supply per dispensing of a covered drug. Note that Medi-Cal quantity per dispensing utilization control limitations on certain opioid containing medications still apply.
- Covering or waiving any prescription delivery costs so that members may receive free prescription delivery.
- Approving out-of-network overrides for members who may be temporarily outside the MCP’s service area due to COVID-19 concerns.
- Setting refill-too-soon edits for maintenance medications to 75 percent or less to authorize early refills when 75 percent of prior prescription has been used. This

---

¹² The Telehealth and Virtual Communications: Payment in FFS and Medi-Cal Managed Care guidance is available on the DHCS COVID-19 Response webpage under Providers & Partners – Guidance for Multiple Provider Types.

¹³ The Guidance for NEMT and NMT Providers is available on the DHCS COVID-19 Response webpage under Providers & Partners – Guidance for Multiple Provider Types.
policy change does not apply to certain medications with quantity/frequency limitations as required by federal and/or state law.

- Expanding pharmacy benefit coverage for all disinfectant solutions and wipes that are able to be processed through the pharmacy benefit systems.
- Ensuring 24/7/365 call center support is available for pharmacies, providers, and members who need support.

In the event of a shortage of any particular prescription drug, MCPs must waive prior authorization and/or step therapy requirements if the member’s prescribing provider recommends the member take a different drug to treat the member’s condition.

**Member Eligibility**

DHCS has delayed Medi-Cal redetermination processing to ensure members continue to have access to services. Members with upcoming redetermination dates will not need to start the redetermination process. Members’ redetermination dates will remain the same, and existing managed care members will continue to be enrolled in their MCP. For more information about these changes, please refer to the Medi-Cal Eligibility Division Information Letters, which can be found on the DHCS COVID-19 Response webpage under Providers & Partners - Eligibility.

Medi-Cal beneficiaries who have active eligibility, but are in an MCP HOLD status of 59 or 61 in the Medi-Cal Eligibility Data System are not without coverage; these individuals would access services through the Medi-Cal FFS providers.

**Encounter Data**

DHCS reminds MCPs that they must submit complete and timely encounter data utilizing all applicable medical coding in a manner consistent with federal guidance, including codes for COVID-19. MCPs should direct specific questions regarding encounter data reporting requirements to MMCDEncounterData@dhcs.ca.gov.

In March 2020, DHCS informed MCPs that it would be temporarily suspending Encounter Validation (EDV) activities for the 2019-2020 State Fiscal Year (SFY) EDV study, including the medical record procurement requirements, in order to minimize non-critical burdens on MCP provider networks during the COVID-19 PHE. In August 2020, DHCS notified MCPs of its intent to resume EDV activities sometime in early 2021, contingent on the state of the COVID-19 PHE. However, because the PHE has continued to carry over into 2021, DHCS has decided that it will no longer be resuming EDV activities, and will instead continue to suspend EDV activities for the 2020-2021 EDV study. In lieu of the SFY 2020-2021 EDV study, DHCS and its contracted External Quality Review Organization are developing an administrative analysis using encounter, provider, and eligibility data to measure encounter data quality.
Health Homes
Based on CMS guidance, DHCS is allowing flexibility for Health Homes Program services to be conducted in a manner that prioritizes the safety of both the providers and the members. In order to minimize the risk of serious illness due to COVID-19, DHCS encourages MCPs and their contracted Community-Based Care Management Entities to implement telephonic and video call assessments to substitute for face-to-face assessments, in compliance with Medi-Cal's telehealth policy, as described above. DHCS will be suspending its current in-person visit requirements until the COVID-19 emergency declaration is rescinded.

Initial Health Assessment
For any members newly enrolled in the MCP between December 1, 2019, and the end of the PHE, DHCS is temporarily suspending the requirement to complete an Initial Health Assessment (IHA), as described in the MCP contract with DHCS, within the timeframes outlined in the contract (120 days for most members). MCPs are permitted to defer the completion of the IHA for these members until the COVID-19 emergency declaration is rescinded; however, DHCS will require the completion of the IHA for these members once the PHE is over.

Quality Monitoring, Programs & Initiatives

1. Quarterly Monitoring:

   DHCS is allowing flexibility on MCP responses to the Quarterly Monitoring Response Template (QMRT). DHCS will continue to send MCP-specific results for all QMRT components through the quarterly monitoring process. However, in order to allow MCPs to prioritize their resources on activities related to COVID-19, MCPs will only be required to submit their responses for B-1: Grievances and B-2: SFHs report, until the COVID-19 emergency declaration is rescinded. MCPs are not required to provide responses on the following components of the QMRT:

   - A-1: Full-Time Equivalent Physician to Member Ratios
   - A-2: Timely Access Survey
   - A-3: Network Report
   - A-4: Mandatory Provider Types
   - A-5: Physician Supervisor to Non-Physician Medical Practitioner Ratios
   - B-3: Out-of-Network Requests

   If DHCS identifies any areas of concern for other quarterly monitoring components, DHCS will work with the MCPs on an individual basis. MCPs should direct questions regarding quarterly monitoring to DHCS-PMU@dhcs.ca.gov.
2. Timely Access Survey:

DHCS has ceased the timely access survey calls to alleviate burden on provider offices during this critical time.

3. Managed Care Program Data Improvement Project

In order to ease administrative demands on MCPs during the COVID-19 response, DHCS is extending the compliance deadline for the Managed Care Program Data Improvement Project (MCPDIP) from July 1, 2020, to July 1, 2021. MCPs that are able to continue MCPDIP activities, complete the necessary testing protocols, and receive approval from DHCS may begin to submit production data for July 2020 as early as August 1, 2020, consistent with the original project schedule. DHCS will continue to support MCPDIP and make technical assistance available to each MCP consistent with the original project schedule.

File and Use

DHCS has approved for MCPs to submit certain documents, including proposed telephone outreach scripts, related to COVID-19 as file and use. File and use means that once an MCP submits the documents or scripts to DHCS, the MCP can immediately begin using those documents or scripts with its members, subject to further DHCS directive. All information communicated to members must be information related to COVID-19 that directly came from DHCS, the California Department of Public Health, or the CDC. In addition, pursuant to HIPAA, the documents or scripts must not contain any Protected Health Information or Personal Information of a member. If there are any edits or changes that need to be made to those documents or scripts after DHCS completes its review, the MCP must make those edits and changes within a specified number of days, as directed by DHCS.

The following documents and scripts have been approved for file and use:

- Robo-calls
- Call campaigns
- Printed mailer communications
- E-mail communications (MCPs choosing to do e-mail communication must also utilize another method of communication because not all members will have an e-mail address on file)
- Texting campaigns (MCPs can only do file and use if they have one or more texting campaigns that have been approved as of June 18, 2019, forward)
Part 3 – SPA 20-0024 Policies

Temporary Reinstatement of Acetaminophen and Cough/Cold Medicines
Primary symptoms of COVID-19 involve pain, aches, fever, and significant cough and congestion. The preferred treatments for these symptoms are over-the-counter fever reducers, analgesics, and cough/cold products. These treatments are often the safest, most effective, and least costly alternatives for the population most at risk of both contracting the virus and subsequently experiencing the most severe symptoms. Therefore, pursuant to SPA 20-0024, DHCS issued guidance on May 13, 2020, regarding the temporary reinstatement of non-legend acetaminophen-containing products and non-legend cough and cold products for adults as covered benefits with the Medi-Cal FFS program. MCPs are required to follow this FFS-issued guidance, including the provision of these over-the-counter drugs without prior authorization.\textsuperscript{14}

Temporary Addition of Provider Types at FQHCs and RHCs
Pursuant to SPA 20-0024, DHCS issued guidance on May 20, 2020, temporarily adding the services of Associate Clinical Social Workers (ACSWs) and Associate Marriage and Family Therapists (AMFTs) at FQHCs and RHCs as billable visits.\textsuperscript{15} The California Board of Behavioral Sciences (BBS) does not consider ACSWs or AMFTs to be licensed practitioners. Therefore, licensed behavioral health practitioners must supervise and assume the professional liability of services furnished by the unlicensed ACSW and AMFT practitioners. The licensed practitioner must also comply with supervision requirements established by the BBS. FQHCs or RHCs can be reimbursed in accordance with the terms of the MCP’s contract with the State related to FQHCs and RHCs for a visit between an FQHC or RHC patient and an ACSW or AMFT. The visit may be conducted as a face to face encounter or meet the requirements of a visit provided via telehealth.

Long Term Care Reimbursement
Approval of SPA 20-0024 enables DHCS to temporarily provide an additional 10 percent reimbursement for LTC per diem rates, effective March 1, 2020.\textsuperscript{16} Unless otherwise

---

\textsuperscript{14} See “Pharmacy- Coverage of Acetaminophen, and Cough and Cold medicines for Adults” on the DHCS COVID-19 Response webpage under Providers & Partners – Hospitals, Pharmacies, Clinics and Other Facilities.

\textsuperscript{15} See “Rural Health Clinics/FQHCs – Associate Clinical Social Worker/Associate Marriage and Family Therapist Services” on the DHCS COVID-19 Response webpage under Providers & Partners – Hospitals, Pharmacies, Clinics and Other Facilities.

\textsuperscript{16} Additional information can be found on the following LTC webpages:
LTC Reimbursement: https://www.dhcs.ca.gov/services/medi-cal/Pages/LTCRU.aspx and LTC Reimbursement AB 1629: https://www.dhcs.ca.gov/services/medi-cal/Pages/AB1629/LTCAB1629.aspx
agreed to between the MCP and the LTC provider, DHCS encourages MCPs to reimburse LTC providers at these LTC per diem rates.

Part 4 – SPA 20-0025
On August 20, 2020, the Centers for Medicare and Medicaid Services (CMS) approved State Plan Amendment 20-0025. The SPA is in accordance with the CMS Interim Final Rule for 42 CFR section 440.30(d) to allow coverage of laboratory tests and x-ray services during the COVID-19 PHE and any future PHE, if the service is to diagnose or detect COVID or the communicable disease named in the PHE. As stated above, MCPs must adhere to the COVID-19 testing requirements outlined in the COVID-19 Virus and Antibody Testing guidance document. For more information please see the COVID-19 Virus and Antibody Testing guidance document, which can be found on the DHCS COVID-19 Response webpage under Providers & Partners – Guidance for Multiple Provider Types.

MCPs are responsible for ensuring that their subcontractors and network providers comply with all applicable state and federal laws and regulations, contract requirements, and other DHCS guidance, including APLs and Policy Letters. MCPs must promptly communicate the substance of this APL to their subcontractors and network providers.

If you have any questions regarding this APL, please contact your MCOD Contract Manager.

Sincerely,

Original Signed by Nathan Nau

Nathan Nau, Chief
Managed Care Quality and Monitoring Division